A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will evaluate the efficacy of intravenous Mircera treatment for the
correction of anemia in patients with chronic kidney disease who are on dialysis. Patients
will be randomized to receive either Mircera 0.6 micrograms/kg i.v. every 2 weeks, or epoetin
3 times per week i.v. according to approved treatment recommendations. The anticipated time
on study treatment is 3-12 months, and the target sample size is 100-500 individuals.